Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumonia Dosing in Critically Ill Patients
2021-003511-25Phase 4Completed
- Sponsor
- CHU Nîmes
- Start
- Sep 2021
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of benzylpenicillin, ceftriaxone, meropenem and piperacillin + tazobactam in pneumonia (4 arms), sponsored by CHU Nîmes. Started Sep 2021; status: completed.
02
Drugs
benzylpenicillinceftriaxonemeropenempiperacillin + tazobactam
03
Conditions
pneumonia
Beyond the preview
Go deeper on 2021-003511-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003511-25.